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Abstract
Rates of invasive fungal infection are highest among neonates, especially those of low birthweight. This study aimed to describe the current
epidemiology of invasive neonatal fungal infections in a UK neonatal infection surveillance network. From 2004 to 2010 prospective
multicentre surveillance was conducted by 14 neonatal units using a web-based database. Clinicians then completed a standardized pro
forma for each positive fungal blood and/or cerebrospinal ﬂuid culture. The overall incidence was 2.4/1000 neonatal unit admissions and was
highest among babies <1000 g (extreme low birthweight, 18.8/1000). Only ﬁve infants (6%) were >1500 g. The majority of infections were
caused by Candida albicans (59; 69%) and Candida parapsilosis (17; 20%); 33% of infants had received antifungal prophylaxis. Known risk
factors (use of central venous catheter, parenteral nutrition, previous antibiotic use) were common among cases. The attributable case
fatality rate was 21% (18/84). Extreme low birthweight infants remain at highest risk of invasive fungal infection and prophylaxis should be
particularly considered for this group. The number needing to receive prophylaxis to prevent one case varies signiﬁcantly among units,
hence unit-speciﬁc decisions are required. Further research is still needed into the optimal empiric and therapeutic strategies.
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Introduction
Invasive fungal infections (IFIs) are an important cause of
morbidity and mortality in preterm or very-low-birthweight
infants (VLBW <1500 g). The majority are due to Candida
species [1]. In the USA an incidence rate of 90/1000
extremely-low-birthweight infants (ELBW <1000 g) was
reported between 2004 and 2007 [2], in contrast to a rate
of 20/1000 ELBW in the UK in 2004 [3]. Mortality attributable
to IFI in neonates ranges from 25 to 55% with neurodevel-
opmental impairment reported in up to 57% [4,5].
A recent analysis of 137 cases of invasive candidiasis in the
USA identiﬁed potentially modiﬁable risk factors including use
of central venous catheters, broad-spectrum antibiotics,
intravenous lipid emulsion, endotracheal tubes and antenatal
antibiotics [2].
There are no recent data on incidence, clinical presentation,
risk factors and outcome of IFI in neonates in the UK. The last
national surveillance study focused on VLBW infants and was
conducted 10 years ago [3]. A recent report from England
described the isolates of invasive Candida infections in children
but had no clinical information [6].
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In 2004 a neonatal infection surveillance network (neonIN)
was established with the objective of collecting clinical and
microbiological data. This study aimed to establish the current
epidemiology of neonatal IFIs to enable evidence-based
decisions to be made regarding prophylaxis and treatment,
and to identify future research directions.
Material and Methods
An episode of IFI was deﬁned as a positive culture from blood
and/or cerebrospinal ﬂuid. Repeatedly positive cultures with the
same fungus were considered to represent the same episode if
there were <14 days between samples. Anonymized data were
prospectively uploaded by each neonatal unit (NNU), and
validated with input from laboratory microbiology data. Further
clinical data were collected retrospectively using a standardized
pro forma for cases recorded between 2004 and 2009, and
prospectively for 2010. Local guidelines for prophylaxis including
date of implementation were provided by the investigators.
Data were analysed using GRAPHPAD PRISM version 6.00 for
Windows (Graphpad Software, La Jolla, CA, USA; www.
graphpad.com). Comparison was made with chi-square test for
normally distributed categorical data or Mann–Whitney U-test
when a normal distribution could not be assumed.
NeonIN received research ethics approval in 2005 (05/
Q0806/34), each participating centre received separate
approval from their local ethics committees.
Results
Over the 7 years of the study, 14 NNUs reported a total of 98
cases of IFI. The number of participating NNUs increased over
the years: seven units between 2004 and 2005, nine between
2006 and 2007, 12 in 2008, 13 in 2009 and 14 in 2010. Twelve of
the units were level 3 and two units were level 2 [7]; seven units
provided surgery, either general/abdominal and/or cardiac.
Incidence
Denominator data (live births and neonatal admissions per
year, split by gestational age and birthweight) were available
for 12 units (reporting 95 cases). The overall incidence was
2.4/1000 NNU admissions. The highest incidence was
reported among ELBW infants (18.8/1000 ELBW infants).
The incidence in VLBW infants was 10.3/1000 VLBW infants.
There was considerable variation between NNUs, ranging
from 0.4 to 7.0/1000 NNU admissions. The incidence was
highest in 2006 (3.9/1000 NNU admissions) and lowest in 2009
(1.6/1000 NNU admissions) (Fig. 1).
Demographics
For 84 infants (86%), demographic and clinical details were
available. The median birthweight was 733 g (range 480–
2610 g, interquartile range (IQR) 620–860 g), the median
gestational age was 25 weeks (range 22–35 weeks). Forty-nine
(58%) were male. The birthweight was >1500 g in ﬁve infants
(6%), four of whom had had abdominal surgery.
Clinical presentation and laboratory investigations
The median age of IFI was 13 days (range 2–84 days, IQR 8–
20 days); early onset infection (within the ﬁrst 6 days)
occurred in 18 cases (21%), only two cases were in the ﬁrst
3 days of life. The majority of infections (90%) had presented
by 30 days of age (94% in ELBW infants) (Fig. 2).
Clinical features and laboratory ﬁndings in the week before
positive cultures were non-speciﬁc. Twenty-seven per cent
(23/84) had severe thrombocytopenia (<50 9 109/L), 26% (22/
84) had neutropenia (<2.5 9 109/L) and 62% (51/84) had a
rising C-reactive protein. Other common features at presen-
tation are reported in Table 1. During the episode the
majority of infants (72/84, 86%) had an elevated C-reactive
protein (>10 mg/L, median 57 mg/L; range 20–282 mg/L, IQR
29–113 mg/L) and 87% (73/84) had thrombocytopenia
(<150 9 109/L; 58% <50 9 109/L).
Most infants (76/83, 92%) had received at least one course of
antibiotics in the week before the fungal episode was diagnosed,
45% (34/76) had received on or two antibiotics and 55% (42/76)
had received two antibiotics. The antibiotics given were narrow
spectrum in 47 infants (62%) (benzylpenicillin or ﬂucloxacillin
with an aminoglycoside) and broad spectrum in 29 (38%) of 78
infants (cephalosporins, meropenem or tazocin).
The presence of associated risk factors such as invasive
ventilation, central vascular catheters and parenteral nutrition
was common (Table 2). Twenty (24%) infants were known to
be colonized with Candida before the invasive episode
(although no unit had routine swab-based surveillance in
place). The median duration between detection of colonization
and invasive disease was 6 days (range 4–26, IQR 5–9 days).
FIG 1. Incidence of invasive fungal infections by year (bars indicate
95% conﬁdence intervals).
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Antifungal prophylaxis had been used in 27/81 (33%) infants,
for a median of 5 days (range 1–10 days, IQR 3–7 days). Ten
of these infants were known to be colonized. Two-thirds of
infants (17/27, 63%) received nystatin, one received miconaz-
ole and the remainder (9/27, 33%) received ﬂuconazole.
Fungal Isolates
Information on fungal isolates was provided for 86 infants. Of
these 59 (69%) were Candida albicans, 17 (20%) Candida
parapsilosis and there was one each of Candida glabrata, Candida
tropicales, Candida guillermondi, Malassezia pachydermatis and
yeasts; in one case both C. albicans and Candida lusitaniae were
isolated and in another case both C. albicans and Malassezia
pachydermatis. Three isolates of Candida were not identiﬁed to
species. Infection with C. albicans occurred earlier, mostly
within the ﬁrst 2 weeks of life (38/47 81% vs 17/37 46%,
p <0.001) whereas C. parapsilosis was more commonly
reported after 2 weeks of age (11/37 30% vs 2/47 4%, p 0.001).
Antifungal prophylaxis policies
Local practices for prophylaxis were known for 11 units. Two
units did not have a policy. The policies of the other nine units
were risk-factor-based, focused mainly on prematurity (<26 or
27 weeks of gestation) or birthweight but incorporating other
factors including previous antibiotic use, presence of ‘fragile
skin’, known fungal colonization, presence of a central venous
catheter or abdominal pathology. Four units used ﬂuconazole,
three units used nystatin, two units used a combination of
these two agents. In ﬁve units prophylaxis was routinely used
already, in four units it was introduced during the study. The
combined incidence for these four units after the introduction
of prophylaxis (12.4/1000 ELBW infants) was signiﬁcantly
lower than that for the two units not using prophylaxis and for
the same four units before implementation of policies (31.5/
1000 ELBW infants, p 0.02).
Additional investigations
In 47 cases (56%) a lumbar puncture was performed. In 6/47
(13%) a positive cerebrospinal ﬂuid culture was obtained (four
C. albicans, two Candida sp.) and in ﬁve additional cases (total
11/47, 24%) the cerebrospinal ﬂuid white cell count was raised
(>20 cells/mm3). None of the 32 cases (38%) who had ocular
screening showed evidence of eye involvement whereas in 4/
58 (7%) there was echocardiogram evidence of intracardiac
fungal infection (endocarditis or a fungal ball). Of the 61 (73%)
who had an abdominal ultrasound performed, four (7%)
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FIG 2. Age at onset by birth weight.
TABLE 1. Clinical signs and laboratory markers at presen-
tation
Presentation n (%)
Rising C-reactive protein 51 (62)
Increasing ventilatory/O2 requirements 37 (44)
Feeding intolerance/gastric aspirates 24 (29)
Temperature instability 22 (27)
Apnoea  bradycardia 22 (27)
Abdominal distension 16 (20)
Hyper/hypoglycaemia 12 (15)
Rising white blood cell count 12 (15)
TABLE 2. Associated factors
Associated factors n (%)
NEC (Bell’s stages I–IV)a 24 (30%)
Respiratory supportb: 73 (92%)
Invasive ventilation 54 (68%)
CPAPc 19 (24%)
≥1 CVCd within 48 h 71 (87%)
Median days in situ 9 days
CVC removed due to fungal infection 51 (61%)
PNe within 48 h 77 (94%)
Trophic feeds within 48 h 52 (63%)
Receipt of
Systemic corticosteroids 8 (10%)
H2 receptor antagonists 10 (12%)
Insulin 16 (20%)
Previous abdominal surgery 11 (13%)
aNEC, necrotizing enterocolitis.
bIn six infants the form of respiratory support was not recorded.
cCPAP, continuous positive airway pressure.
dCVC, central venous catheter.
eParenteral nutrition.
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showed lesions indicative of a fungal infection (one hepatic,
one renal, one both, in one case the site was not recorded).
Antifungal treatment
In 16 cases treatment had been started empirically, a median of
7.5 days (range 3–12 days, IQR 3–10 days) before the fungal
culture was reported.
In 77 cases, information on deﬁnitive treatment was
provided and in 48 cases doses were also reported: 42
(55%) received ﬂuconazole (3–12 mg/kg), 26 (34%) received
amphotericin B liposomal (1–10 mg/kg) and 9 (12%) received
amphotericin B deoxycholate (0.65–1 mg/kg) as ﬁrst-line
treatment (one died before receiving treatment and treatment
was not speciﬁed in ﬁve). In 32 cases (42%) the initial fungal
treatment was changed: in 29 (38%) from ﬂuconazole to
liposomal amphotericin B (23) or amphotericin B deoxycholate
(6). In one case amphotericin B deoxycholate was changed to
liposomal amphotericin B and in one case each ﬂuconazole was
changed to amphotericin B deoxycholate or liposomal ampho-
tericin B. The median duration of treatment in survivors was
25 days (range 9–137 days, IQR 17–45 days).
Outcome
Twenty-six (31%) of the 84 infants died and all were ELBW. In
18 cases (21%) IFI contributed to the death according to the
treating clinician. The median postnatal age at death was
31 days (range 11–55 days, IQR 19–40 days). Fourteen (54%)
of those who died had been treated with liposomal ampho-
tericin B, eight (31%) with ﬂuconazole and one with ampho-
tericin B deoxycholate. There was a signiﬁcantly higher
proportion of deaths in infants treated with liposomal
amphotericin B than those treated with ﬂuconazole [p 0.002
(0.0016)]. The median duration of treatment of those who
died was 16 days (range 5–57 days, IQR 11–27 days). There
were no signiﬁcant differences between those who died and
those who survived with regard to birthweight, age at
presentation, deﬁnitive therapy used, or management of
central venous catheter (data not shown). There was no
signiﬁcant difference in infants in whom empiric therapy was
started (6/16, 38%) compared with those where antifungals
were started after cultures became positive (32%, p 0.69). Of
note, involvement of other organs was recorded in 31% of
those who died (8/26, two with meningitis, four (of four) with
intracardiac and two (of four) with abdominal lesions).
Discussion
We report the largest series of invasive neonatal fungal
infections from the UK. The majority (83%) of infections (and
all of the deaths) occurred in ELBW infants (incidence of 18.8/
1000), conﬁrming this group to be at highest risk. Interestingly,
this incidence is signiﬁcantly lower than that reported from
North America between 2004 and 2007 (90/1000; or 69/1000
excluding urine samples) [2]. However, recommendations on
antifungal prophylaxis and central venous catheter care have
since been instituted in the USA and may have reduced this
incidence.
In our study the majority of cases were due to C. albicans
(68%) and C. parapsilosis (20%). This is consistent with data
from the USA and from a recent national UK study (2000–
2009) [6]. In both studies, no increase in the incidence of
non-albicans species has been observed over time, in contrast
to other reports [8].
The overall incidence in VLBW infants in our study was
10.3/1000 and the previous UK national surveillance study
reported a similar incidence (based on positive cultures from
blood and cerebrospinal ﬂuid) [3]. However, there was a
noticeable decline in incidence of IFI in our network after
2006. All units introducing antifungal prophylaxis policies
during our study implemented them subsequently, in 2008, so
this does not adequately explain the decline. It is possible
that introduction of a nationwide campaign in the mid-2000s
to reduce healthcare-associated infections, which included
measures to reduce central venous catheter-related infec-
tions, has also had a beneﬁcial impact on IFIs [9] In support
of this hypothesis, a study from the USA has shown that the
incidence of central venous catheter-associated bloodstream
infections due to Candida spp. decreased by 75% among
NNU patients between 1999 and 2009 in the context of
initiatives around improved central line insertion and main-
tenance [10].
Wide variation in the incidence between otherwise similar
academic tertiary NNUs has been reported previously [2,11].
Demographic characteristics of the patient population are
potential sources; other recognized and potentially modiﬁable
factors include practices around mechanical ventilation, use of
central lines, parenteral nutrition and empiric antibiotic
policies. In one study, invasive candidiasis was shown to be
directly related to the average number of days of broad-spec-
trum antibiotics received [12]. The use of cephalosporins in
UK NNUs is generally low [13] and although exposure to
antibiotics in the week before the IFI was extremely common
in this study (90%), 62% received only narrow-spectrum
antibiotics.
There is clear published evidence that prophylaxis can
reduce the incidence of IFI [14–16]. Our study also shows that
units implementing prophylaxis policies have a lower incidence
of IFI. However, the most appropriate agent (nystatin or
ﬂuconazole), target group, and the cost-effectiveness of
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prophylaxis in different settings are still not clear [17].
Prophylaxis has been recommended for high incidence centres
in the USA since 2009 [18].
For all neonIN centres combined, the number of ELBW
infants that would need to be treated prophylactically to prevent
one case of IFI (assuming 100% efﬁcacy) is 60 (62/3727).
However, this ranges from 33 (13/436) to 622 (1/622) for
different centres within the network. Knowledge of unit-speciﬁc
disease rates should allow individual units to decide on their
need for prophylaxis [19]. The duration of prophylaxis can be
basedon the age until which disease naturally occurs; as the great
majority has occurred by 30 days of age, prophylaxis can inmost
cases be safely stopped thereafter.
Different strategies have been proposed to better deﬁne
those infants with suspected IFI at an early stage and therefore
allow timely targeted empiric therapy [19]. It is clear from our
data, however, that the clinical presentation with IFI is difﬁcult
to differentiate from that of other serious bacterial infections
[20]. In one study, a combination of extreme prematurity
(<25 weeks), thrombocytopenia (<150 9 109/L), and use of
broad-spectrum antibiotics in the 5–7 days before the onset of
the suspected infection were identiﬁed as sufﬁciently discrim-
inatory to use as a guide for starting empiric antifungal therapy
[21]. In our study this algorithm would have correctly
identiﬁed 36 cases (37%) and indeed ten of these had received
empiric antifungal therapy. However, the case fatality in the
group treated empirically and the group treated after a positive
blood culture was not signiﬁcantly different, so the effective-
ness of empiric treatment needs to be studied in an
appropriately designed trial.
The ideal therapy for proven candidaemia is uncertain [22].
Our study reveals that, in common with other published
studies [23,24] liposomal amphotericin B is increasingly used
for deﬁnitive treatment. However, a recent study identiﬁed a
worse outcome in those receiving lipid-based amphotericin B,
compared with amphotericin B deoxycholate or ﬂuconazole
[25]. In our study there was a signiﬁcantly higher proportion of
deaths in infants treated with liposomal amphotericin B
compared with those treated with ﬂuconazole. This apparent
discrepancy may be due to the clinicians’ choice of liposomal
amphotericin B in the most clinically unwell infants, neverthe-
less this difference in treatment outcomes should be urgently
addressed.
Our study has several limitations. Data collection was partly
retrospective, although there did not appear to be any
differences in the quality of data collected retrospectively
compared with that collected prospectively. It was also a
descriptive study and therefore it was not possible to further
analyse the associations with potential risk factors as we did
not have a control group. We also recognize that this study
reﬂects the minimum incidence of IFI because we did not
include cases where only urine cultures were positive.
As the overall incidence of IFI is low and varies between
units and countries, multicentre and international collabora-
tions are required to identify and initiate further studies in
this area. Outstanding research questions include the most
cost-effective agents for prophylaxis and deﬁnitive therapy
and the beneﬁts and components of an optimal treatment
strategy.
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